GlassScriptPhysician profile
Daniell Mcsweeny
NPI 1295352482
$5,820.68
in general payments reported to CMS, 2019-2025
33 companies · $1,110 in 2025
The $1,110 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,314 · 2022: $1,260 · 2023: $881 · 2024: $1,256 · 2025: $1,110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,063 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,062.56 |
| Education | $183.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,333.62 | 2021-2025 | |
| Novo Nordisk INC | $620.95 | 2021-2025 | Wegovy |
| Astellas Pharma US INC | $472.73 | 2021-2025 | Veozah, Myrbetriq |
| Currax Pharmaceuticals LLC | $427.06 | 2021-2024 | Contrave |
| Pfizer INC. | $304.26 | 2023-2025 | |
| Amgen INC. | $276.13 | 2021-2025 | Evenity, Prolia, Prolia |
| Mayne Pharma Commercial LLC | $238.47 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $182.48 | 2023-2025 | Myfembree, Gemtesa |
| Myriad Women'S Health, INC. | $180.21 | 2023 | Myrisk |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $161.31 | 2021-2025 | Xifaxan, Trulance |
| Therapeuticsmd, INC. | $153.99 | 2021-2022 | |
| Corcept Therapeutics | $141.14 | 2021 | |
| Aspira Women'S Health INC | $112.47 | 2022 | |
| Lilly USA, LLC | $109.12 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Ibsa Pharma INC. | $90.85 | 2021-2024 | Tirosint, Licart, Tirosint |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $90.41 | 2022-2025 | Slynd |
| Biohaven Pharmaceutical Holding Company LTD. | $88.68 | 2022 | |
| Nestle Healthcare Nutrition INC. | $85.92 | 2021-2023 | |
| Mylan Pharmaceuticals INC. | $83.11 | 2021-2022 | |
| Shield Therapeutics INC | $81.33 | 2024-2025 | |
| Biohaven Pharmaceuticals, INC. | $80.44 | 2021 | |
| Exact Sciences Corporation | $72.51 | 2023-2025 | Cologuard Collection Kit |
| Aimmune Therapeutics, INC. | $68.32 | 2024-2025 | Zenpep |
| Hologic Sales and Service, LLC | $56.75 | 2024-2025 | Aptima |
| Millicent US INC | $56.63 | 2025 | Femlyv |
| Myovant Sciences INC. | $54.91 | 2021-2022 | |
| Daiichi Sankyo INC. | $35.25 | 2021 | |
| Organon LLC | $34.67 | 2024 | |
| Alfasigma USA, INC. | $33.38 | 2022 | |
| Acella Pharmaceuticals, LLC | $28.74 | 2025 | NP Thyroid 60 |
| Lupin INC. | $26.99 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.03 | 2021 | |
| Evofem Biosciences, INC. | $15.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniell Mcsweeny listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.